Company news
Optimi Health Corp. news in 2026
Optimi Health Corp.'s news releases, calls and decks from 2026, newest first.
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
October 26, 2026
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
October 20, 2026
Optimi Health to Present at the ThinkEquity Conference
October 7, 2026
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
September 16, 2026
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Optimi Health Establishes Discretionary Equity Facility
August 14, 2026
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
June 29, 2026
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
June 16, 2026
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
June 10, 2026
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
June 8, 2026
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
June 2, 2026
Optimi Health (OPTH) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
May 29, 2026
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
May 29, 2026
Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)
May 27, 2026
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
May 26, 2026
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
May 21, 2026
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
May 20, 2026
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
April 23, 2026
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
April 20, 2026
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
March 16, 2026
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
February 26, 2026
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
February 19, 2026
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
February 17, 2026
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
February 9, 2026
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
January 26, 2026
Early Warning Press Release in Accordance with National Instrument 62-103
January 21, 2026
Optimi Health Announces Equity Incentive Grants and Corporate Update
January 16, 2026
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
January 14, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 22 slides · September 2026